Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab.

Abstract

OBJECTIVES To survey possible funding models and pricing practices as well as prices for the treatment package of trastuzumab and its accompanying diagnostic test in European countries, as an example of personalised medicines. METHODS Qualitative descriptive data on national pharmaceutical pricing and funding policies applied to trastuzumab and its… (More)

Topics

Cite this paper

@article{Leopold2013PersonalisedMA, title={Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab.}, author={Claudia Sabine Leopold and Steffen Vogler and Claudia Habl and Aukje K. Mantel-Teeuwisse and Jos{\'e} Carlos Esp{\'i}n}, journal={Health policy}, year={2013}, volume={113 3}, pages={313-22} }